Abstract: Embodiments of the present application provide Ensartinib or a salt thereof and a use of a composition containing Ensartinib or the salt thereof in treatment of a disease carrying MET 14 exon skipping mutation.

Abstract: The present disclosure relates to the field of luminescent materials of blue phosphorescent tetradentate cyclopalladated palladium complexes, and discloses a trisubstituted pyrazole based blue phosphorescent tetradentate cyclopalladated palladium complex, preparation and use thereof. The complex may be a delayed fluorescent and/or phosphorescent emitter, has a high thermal decomposition temperature, can perform blue luminescent, and has strong light emitting, and thus has a great application prospect in the field of blue light, and especially deep blue phosphorescent materials.

Abstract: The present disclosure relates to the field of blue phosphorescent tetradentate cyclic-metal palladium complex luminescent materials, and discloses a blue phosphorescent tetradentate cyclic-metal palladium complex based on 4-aryl-3,5-disubstituted pyrazol, preparation and use thereof. The complex may be a delayed fluorescent and/or phosphorescent emitter. The complex has characteristics of high thermal decomposition temperature, high luminous intensity, and deep blue light emission and a narrow emission spectrum, therefore there are a huge application prospects in the field of blue light, especially in deep blue phosphorescent materials.

Abstract: The invention relates to the technical field of organic luminescent materials, in particular to a binuclear organometallic complex, its luminescent devices and its application. The binuclear organometallic complexes of the invention are at least one of the compounds shown in the selected from the general formula I. The luminescent interval of the binuclear organometallic complexes of the invention is in the range of 400 nm to about 700 nm, compared with the traditional complexes, the binuclear organometallic complexes of the invention have improved stability and efficiency.

Abstract: The invention relates to the technical field of organic luminescent materials, in particular to a binuclear organometallic complex and its application. The binuclear organometallic complexes of the invention are at least one of the compounds shown in the selected from general formula I. The luminescent interval of the binuclear organometallic complexes of the invention is in the range of 400 nm to about 700 nm, compared with the traditional complexes, the binuclear organometallic complexes of the invention have improved stability and efficiency.

Abstract: Disclosed herein are multidentate dinuclear cyclometallated complexes. The complexes are suitable as emitting materials or host materials in OLED devices.

Abstract: Disclosed herein are multidentate dinuclear cyclometallated complexes.

Abstract: Disclosed herein are multidentate dinuclear cyclometallated platinum complexes.

Abstract: Disclosed herein are multidentate dinuclear cyclometallated complexes. The complexes are suitable as emitting materials or host materials in OLED devices.

Abstract: Disclosed herein are multidentate dinuclear cyclometallated complexes.

Abstract: Disclosed herein are multidentate dinuclear cyclometallated platinum complexes.

Abstract: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar.

Abstract: The present invention provides a liver preservation solution containing trehalose and dibutyryl-cAMP. The content of nitroglycerin in the preservation solution is preferably lower than 0.44 mM. In the liver preservation solution of the present invention, since the toxicity due to nitroglycerin, which is observed during liver preservation, has been improved, liver transplantation can be performed with a high engrafted rate.

Abstract: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.

Abstract: The present invention provides a liver preservation solution containing trehalose and dibutyryl-cAMP. The content of nitroglycerin in the preservation solution is preferably lower than 0.44 mM. In the liver preservation solution of the present invention, since the toxicity due to nitroglycerin, which is observed during liver preservation, has been improved, liver transplantation can be performed with a high engrafted rate.

Abstract: The present invention provides a liver preservation solution containing trehalose and dibutyryl-cAMP. The content of nitroglycerin in the preservation solution is preferably lower than 0.44 mM. In the liver preservation solution of the present invention, since the toxicity due to nitroglycerin, which is observed during liver preservation, has been improved, liver transplantation can be performed with a high engrafted rate.

Abstract: A method and system of dynamically collecting waste ink in a printing system is disclosed. The method includes providing a collection reservoir for the waste ink wherein the waste ink has a conductance, positioning at least two electrodes in the collection reservoir and sensing the conductance of the waste ink so as to determine when the collection reservoir needs to be serviced.

Abstract: An imaging device includes an ink collection structure.